Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis-Reference-Cited by-同舟云学术

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis

Published:2018-08-17 Issue:6 Volume:119 Page:713-723
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Krisp Christoph,Parker Robert,Pascovici Dana,Hayward Nicholas K.,Wilmott James S.,Thompson John F.,Mann Graham J.,Long Georgina V.,Scolyer Richard A.,Molloy Mark P.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0227-2.pdf

Reference65 articles.

1. Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).

2. Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175 (2017).

3. Kunz, M. The genetic basis of new treatment modalities in melanoma. Curr. Drug Targets 16, 233–248 (2015).

4. Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).

5. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dataset: Impact of β-Galactosylceramidase Overexpression on the Protein Profile of Braf(V600E) Mutated Melanoma Cells;Data;2023-11-24

2. Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report;Case Reports in Oncology;2023-11-24

3. The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells;International Journal of Molecular Sciences;2023-06-23

4. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies;eBioMedicine;2023-06

5. Proteomic profiling of cutaneous melanoma explains the aggressiveness of distant organ metastasis;Experimental Dermatology;2023-04-21